Iversun is a highly effective, broad-spectrum antiparasitic medication formulated with the active ingredient ivermectin. Designed for the treatment of a range of parasitic infestations, including strongyloidiasis and onchocerciasis, it operates by paralyzing and eliminating parasitic organisms, thereby alleviating symptoms and preventing disease progression. Its well-documented efficacy and favorable safety profile make it a cornerstone in clinical parasitology, trusted by healthcare professionals worldwide for targeted therapeutic intervention.

Features

• Contains ivermectin as the active pharmaceutical ingredient
• Available in standardized 3 mg and 6 mg oral tablets
• Manufactured under strict GMP (Good Manufacturing Practice) guidelines
• Bioequivalent to reference listed drugs
• Shelf-stable formulation with clearly marked expiration dating
• Child-resistant packaging for enhanced safety

Benefits

• Effectively eliminates target parasites, reducing parasitic load and associated morbidity
• Alleviates clinical symptoms such as pruritus, skin lesions, and gastrointestinal distress
• Helps prevent long-term complications of chronic parasitic infections, including blindness in onchocerciasis
• Supports public health initiatives in endemic regions by interrupting transmission cycles
• Offers a well-tolerated treatment option with a single or short-course dosing regimen in many cases
• Contributes to improved quality of life and reduced disability-adjusted life years (DALYs)

Common use

Iversun is indicated for the treatment of parasitic infections caused by nematodes and ectoparasites. Its primary uses include the treatment of strongyloidiasis of the intestinal tract, caused by Strongyloides stercoralis, and onchocerciasis (river blindness), caused by Onchocerca volvulus. It may also be used off-label under medical supervision for other parasitic conditions, such as scabies and certain cases of filariasis, based on healthcare provider assessment and regional guidelines.

Dosage and direction

Dosage is based on body weight and the specific infection being treated. It is imperative to follow the prescribing physician’s instructions precisely.

• For strongyloidiasis: A single oral dose of 200 mcg per kilogram of body weight.
• For onchocerciasis: A single oral dose of 150 mcg per kilogram of body body weight; retreatment may be required every 3 to 12 months depending on clinical presentation and geographic protocols.
• Tablets should be taken on an empty stomach with a full glass of water to maximize absorption.
• Do not crush or chew tablets; swallow whole.

Dosing in children and individuals with hepatic impairment requires careful medical evaluation and potential adjustment.

Precautions

• A thorough medical history should be obtained prior to initiation, with emphasis on liver function, immune status, and travel history.
• Use with caution in elderly patients and those with compromised hepatic function.
• May cause dizziness or drowsiness; patients should avoid driving or operating heavy machinery until they know how Iversun affects them.
• Not recommended during pregnancy unless the potential benefit justifies the potential risk to the fetus.
• Breastfeeding should be discontinued during treatment, as ivermectin is excreted in human milk.

Contraindications

Iversun is contraindicated in:

• Patients with a known hypersensitivity to ivermectin or any component of the formulation.
• Individuals with concomitant loiasis (Loa loa infection) in regions where both onchocerciasis and loiasis are endemic, due to the risk of serious encephalopathic reactions.
• Use in children weighing less than 15 kg is generally not recommended unless under direct specialist supervision.

Possible side effects

Most adverse reactions are mild and transient. Common side effects may include:

• Diarrhea, nausea, or abdominal pain
• Dizziness, drowsiness, or vertigo
• Pruritus, rash, or urticaria
• Transient elevation in liver enzymes

Less frequently, patients may experience:

• Orthostatic hypotension
• Swelling of the face or extremities
• Worsening of asthma in susceptible individuals

Serious adverse effects are rare but may include severe skin reactions, hepatitis, or neurological events such as ataxia. Seek immediate medical attention if severe symptoms occur.

Drug interaction

Iversun is primarily metabolized by CYP450 enzymes. Concomitant use with other agents that induce or inhibit these enzymes may alter plasma concentrations.

• Caution is advised when co-administered with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir), which may increase ivermectin levels.
• Warfarin: Monitor INR closely, as ivermectin may potentiate anticoagulant effect.
• Certain anticonvulsants (e.g., carbamazepine, phenytoin) may reduce ivermectin efficacy.
• Always inform your healthcare provider of all medications, including over-the-counter drugs and herbal supplements.

Missed dose

If a dose is missed, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. In most treatment regimens involving Iversun, dosing is single or intermittent; consult your prescriber for specific guidance.

Overdose

Symptoms of overdose may include exaggerated side effects such as severe nausea, vomiting, diarrhea, dizziness, pupillary dilation, and ataxia. In cases of significant overdose, hypotension and respiratory depression may occur. There is no specific antidote; treatment is supportive and symptomatic. Gastric lavage and activated charcoal may be considered if ingestion was recent. Immediate medical attention is required.

Storage

Store at room temperature (15–30°C or 59–86°F) in a dry place, protected from light and moisture. Keep in the original container. Do not use after the expiration date printed on the packaging. Keep out of reach of children and pets.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or changing your treatment plan. Dosage and indications may vary based on regional approvals and individual patient factors. The manufacturer is not liable for misuse or incorrect application of this product.

Reviews

Dr. Elena Rostova, Infectious Disease Specialist: “Iversun has been instrumental in our tropical medicine clinic. Its predictable efficacy and manageable side effect profile allow for successful outpatient management of complex parasitic diseases.”

Global Health Initiative Report, 2023: “In mass drug administration programs, Iversun has demonstrated high compliance rates and significant reduction in microfilarial loads, supporting its role in disease elimination campaigns.”

Clinical Pharmacist Review: “The bioequivalence and consistency of Iversun make it a reliable choice for formulary inclusion. Its stability in challenging storage conditions is particularly valuable in field use.”